Rise in Shares for Biogen, Eisai as Alzheimer’s Drug Succeeds in Mid-Stage Trial.
July 9, 2018
Source: Reuters
709
In a breakthrough finding, revealed through the final analysis of a mid-stage trial, Japanese pharmaceutical firm, Eisai Co and Biogen Inc’s drug for Alzheimer’s proved beneficial for patients who received the highest dose.
This catapulted Eisai’s shares up by 14.6 percent in Friday morning trading in Tokyo and Biogen’s shares by 7 percent at $320 in after-hours trading.
In a statement on July 5, the companies announced that the highest dose of the drug BAN2401 decelerated disease progression significantly at the end of 18 months compared to a placebo. The trial was carried out on 856 patients with early Alzheimer’s who were following five dose regimens.
BAN2401, among several other drugs, acts by targeting beta-amyloid, a protein that forms toxic brain plaques which are believed to be an underlying cause of this degenerative the disease.
To date, there haven’t been any positive outcomes of drug trials in slowing the progression of Alzheimer’s disease. Current drugs can do no more than give symptomatic relief.
Biogen and Eisai said in their statement on Thursday that the complete findings of the final analysis of the mid-stage trial will be made public at a future conference.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Disposable Medical Products that Keep Your Medical Facility Clean and Sterile March 31, 2022
- 10 Triumphant Drug Launches Of The Decade August 26, 2021
- Closing In On The Cause Of Alzheimer’s Disease December 2, 2020
- Significant Approvals, Diabetes And NASH In India, Japan M&A January 8, 2020
- Ultrasonic Nebulizer Market Views September 6, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
